

Special Issue

New Directions for Treating Soft Tissue Sarcomas

Message from the Guest Editors

In recent decades, there have been several developments in treatment strategies for soft tissue sarcomas (STS) to improve patient outcomes. Currently, there is more insight into the differences in biological behavior and molecular background between the different sarcoma histotypes leading to more focused treatment strategies for specific subtypes. The centralization of sarcoma care and more (international) collaboration in sarcoma research also seem to improve the quality of care. However, given the heterogeneity of the disease and the rarity of the different subtypes, setting up clinical trials for STS remains challenging. Furthermore, there have been no major breakthroughs with new targeted agents or immuno-oncology strategies when compared to other cancer types. To further improve cure and care for sarcoma patients, this Special Issue will highlight new research directions and multi-disciplinary treatment strategies for patients with STS, in primary, recurrent, and metastatic settings.

Guest Editors

Dr. Winan J. van Houdt

Department of surgical oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

Prof. Dr. Bernd Kasper

University of Heidelberg, Mannheim University Medical Center, Sarcoma Unit, Theodor-Kutzer-Ufer 1-3, D-68167 Mannheim, Germany

Deadline for manuscript submissions

closed (31 May 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/63078

Cancers

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)